Literature DB >> 26468535

Respiratory Syncytial Virus Attachment Glycoprotein Contribution to Infection Depends on the Specific Fusion Protein.

Jia Meng1, Anne L Hotard1, Michael G Currier1, Sujin Lee1, Christopher C Stobart1, Martin L Moore2.   

Abstract

UNLABELLED: Human respiratory syncytial virus (RSV) is an important pathogen causing acute lower respiratory tract disease in children. The RSV attachment glycoprotein (G) is not required for infection, as G-null RSV replicates efficiently in several cell lines. Our laboratory previously reported that the viral fusion (F) protein is a determinant of strain-dependent pathogenesis. Here, we hypothesized that virus dependence on G is determined by the strain specificity of F. We generated recombinant viruses expressing G and F, or null for G, from the laboratory A2 strain (Katushka RSV-A2GA2F [kRSV-A2GA2F] and kRSV-GstopA2F) or the clinical isolate A2001/2-20 (kRSV-2-20G2-20F and kRSV-Gstop2-20F). We quantified the virus cell binding, entry kinetics, infectivity, and growth kinetics of these four recombinant viruses in vitro. RSV expressing the 2-20 G protein exhibited the greatest binding activity. Compared to the parental viruses expressing G and F, removal of 2-20 G had more deleterious effects on binding, entry, infectivity, and growth than removal of A2 G. Overall, RSV expressing 2-20 F had a high dependence on G for binding, entry, and infection. IMPORTANCE: RSV is the leading cause of childhood acute respiratory disease requiring hospitalization. As with other paramyxoviruses, two major RSV surface viral glycoproteins, the G attachment protein and the F fusion protein, mediate virus binding and subsequent membrane fusion, respectively. Previous work on the RSV A2 prototypical strain demonstrated that the G protein is functionally dispensable for in vitro replication. This is in contrast to other paramyxoviruses that require attachment protein function as a prerequisite for fusion. We reevaluated this requirement for RSV using G and F proteins from clinical isolate 2-20. Compared to the laboratory A2 strain, the G protein from 2-20 had greater contributions to virus binding, entry, infectivity, and in vitro growth kinetics. Thus, the clinical isolate 2-20 F protein function depended more on its G protein, suggesting that RSV has a higher dependence on G than previously thought.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26468535      PMCID: PMC4702574          DOI: 10.1128/JVI.02140-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.

Authors:  M N Teng; S S Whitehead; P L Collins
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

2.  Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus.

Authors:  Sunee Techaarpornkul; Peter L Collins; Mark E Peeples
Journal:  Virology       Date:  2002-03-15       Impact factor: 3.616

3.  A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Kelsey A Gaston; Sean O Todd; Cemil Boyoglu; Tatiana Chirkova; Thomas R Barnum; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

4.  Identification of glycosaminoglycans in human airway secretions.

Authors:  Maria E Monzon; Susana M Casalino-Matsuda; Rosanna M Forteza
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09-29       Impact factor: 6.914

5.  Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.

Authors:  S A Feldman; R M Hendry; J A Beeler
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.

Authors:  L K Hallak; D Spillmann; P L Collins; M E Peeples
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity.

Authors:  Laura K White; Jeong-Joong Yoon; Jin K Lee; Aiming Sun; Yuhong Du; Haian Fu; James P Snyder; Richard K Plemper
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

8.  A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis.

Authors:  Anne L Hotard; Fyza Y Shaikh; Sujin Lee; Dan Yan; Michael N Teng; Richard K Plemper; James E Crowe; Martin L Moore
Journal:  Virology       Date:  2012-10-11       Impact factor: 3.616

9.  IL-27R-mediated regulation of IL-17 controls the development of respiratory syncytial virus-associated pathogenesis.

Authors:  Denise E de Almeida Nagata; Tine Demoor; Catherine Ptaschinski; Hung-An Ting; Sihyug Jang; Michelle Reed; Sumanta Mukherjee; Nicholas W Lukacs
Journal:  Am J Pathol       Date:  2014-04-13       Impact factor: 4.307

10.  The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection.

Authors:  Kate L Stokes; Michael G Currier; Kaori Sakamoto; Sujin Lee; Peter L Collins; Richard K Plemper; Martin L Moore
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

View more
  13 in total

1.  A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.

Authors:  Christina A Rostad; Christopher C Stobart; Brian E Gilbert; Ray J Pickles; Anne L Hotard; Jia Meng; Jorge C G Blanco; Syed M Moin; Barney S Graham; Pedro A Piedra; Martin L Moore
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

2.  CX3CR1 Engagement by Respiratory Syncytial Virus Leads to Induction of Nucleolin and Dysregulation of Cilia-related Genes.

Authors:  Christopher S Anderson; Tatiana Chirkova; Christopher G Slaunwhite; Xing Qiu; Edward E Walsh; Larry J Anderson; Thomas J Mariani
Journal:  J Virol       Date:  2021-03-17       Impact factor: 5.103

3.  A Respiratory Syncytial Virus Attachment Gene Variant Associated with More Severe Disease in Infants Decreases Fusion Protein Expression, Which May Facilitate Immune Evasion.

Authors:  Stacey Human; Anne L Hotard; Larry J Anderson; Tina V Hartert; Martin L Moore; Christina A Rostad; Sujin Lee; Louise McCormick; Emma K Larkin; Teresa C T Peret; Jaume Jorba; Joseph Lanzone; Tebeb Gebretsadik; John V Williams; Melissa Bloodworth; Matthew Stier; Kecia Carroll; R Stokes Peebles
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

4.  EGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin Expression.

Authors:  Michael G Currier; Sujin Lee; Christopher C Stobart; Anne L Hotard; Remi Villenave; Jia Meng; Carla D Pretto; Michael D Shields; Minh Trang Nguyen; Sean O Todd; Michael H Chi; Jason Hammonds; Stefanie A Krumm; Paul Spearman; Richard K Plemper; Kaori Sakamoto; R Stokes Peebles; Ultan F Power; Martin L Moore
Journal:  PLoS Pathog       Date:  2016-05-06       Impact factor: 6.823

5.  A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation.

Authors:  Christopher C Stobart; Christina A Rostad; Zunlong Ke; Rebecca S Dillard; Cheri M Hampton; Joshua D Strauss; Hong Yi; Anne L Hotard; Jia Meng; Raymond J Pickles; Kaori Sakamoto; Sujin Lee; Michael G Currier; Syed M Moin; Barney S Graham; Marina S Boukhvalova; Brian E Gilbert; Jorge C G Blanco; Pedro A Piedra; Elizabeth R Wright; Martin L Moore
Journal:  Nat Commun       Date:  2016-12-21       Impact factor: 14.919

6.  Alternative conformations of a major antigenic site on RSV F.

Authors:  Harrison G Jones; Michael B Battles; Chun-Chi Lin; Siro Bianchi; Davide Corti; Jason S McLellan
Journal:  PLoS Pathog       Date:  2019-07-15       Impact factor: 6.823

Review 7.  Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem.

Authors:  Ralph A Tripp; Ultan F Power; Peter J M Openshaw; Lawrence M Kauvar
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

8.  Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.

Authors:  Jarrod J Mousa; Elad Binshtein; Stacey Human; Rachel H Fong; Gabriela Alvarado; Benjamin J Doranz; Martin L Moore; Melanie D Ohi; James E Crowe
Journal:  PLoS Pathog       Date:  2018-02-22       Impact factor: 6.823

Review 9.  Structural Insight into Paramyxovirus and Pneumovirus Entry Inhibition.

Authors:  Megha Aggarwal; Richard K Plemper
Journal:  Viruses       Date:  2020-03-20       Impact factor: 5.048

10.  Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development.

Authors:  Julia Dubois; Andrés Pizzorno; Marie-Hélène Cavanagh; Blandine Padey; Claire Nicolas de Lamballerie; Olus Uyar; Marie-Christine Venable; Julie Carbonneau; Aurélien Traversier; Thomas Julien; Sophie Lavigne; Christian Couture; Bruno Lina; Marie-Ève Hamelin; Olivier Terrier; Manuel Rosa-Calatrava; Guy Boivin
Journal:  Vaccines (Basel)       Date:  2019-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.